PulseExploreJournal ClubDebatesTrendingResearchersJournals
Instagram
HomeExploreJournal ClubTrending
Synapse
⌘+K
Synapse
March 3, 20260 citations

Immunomodulators in the Treatment of Atherosclerosis and Other Chronic Heart Diseases: Prospects and Risks.

YTYu. V. TyravskaDMDmytro MaltsevVMV Moyseyenko

Key Points

  • Immunosuppressive therapy safety profiles remain critical for monitoring infectious complications and oncological risks.
  • Decade-long surveillance across diverse populations is essential for understanding long-term impacts.
  • Safety assessments focus on atherogenesis and its relation to chronic heart diseases, revealing emerging risks.
  • Long-term studies can inform best practices and guide future research directions in chronic conditions.

Abstract

Long-term monitoring of immunosuppressive therapy safety profiles, particularly regarding infectious complications and oncological risks, remains critically important for future large-scale studies requiring decade-long surveillance in diverse populations.

Ask AI
Helpful
Bookmark
Share

Cite This Study

Tyravska et al. (2025) studied this question.

synapsesocial.com/papers/69a76169c6e9836116a2f50d
Ask AI
Helpful
Bookmark
Share